Journals / Türk Dermatoloji Dergisi / 2020 / Cilt: 14 - Sayı: 1

A Psoralen and Ultraviolet A‑Aggravated Dermatosis: Grover’s Disease

Pages
25–27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The current report describes the case of GD in a female patient, which was aggravated by the psoralen and UVA phototherapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Grover’s disease (GD) is an acquired dermatosis called transient acantholytic dermatosis.
📊
Key Findings & Data:The exact cause is unknown, but the factors blamed for the etiology include ultraviolet (UV), sweating, temperature rise, radiation, medications, and malignancies.
💡
Conclusion & Impact:The current report describes the case of GD in a female patient, which was aggravated by the psoralen and UVA phototherapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Grover’s disease (GD) is an acquired dermatosis called transient acantholytic dermatosis. The exact cause is unknown, but the factors blamed for the etiology include ultraviolet (UV), sweating, temperature rise, radiation, medications, and malignancies. Topical corticosteroids, topical retinoids, and topical calcipotriol are usually sufficient for treatment, and systemic retinoids, systemic steroids, phototherapy, and methotrexate are rarely used. The current report describes the case of GD in a female patient, which was aggravated by the psoralen and UVA phototherapy.

🔖

Cite This Article

OZLU, E., KARADAG, A. S., UZUNCAKMAK, T. K., OZKANLI, S., ERDEM, A., AKDENİZ, N. (2020). A Psoralen and Ultraviolet A‑Aggravated Dermatosis: Grover’s Disease. Türk Dermatoloji Dergisi, Cilt: 14 - Sayı: 1, 25–27. https://ajindex.com/articles/394944

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Aldana PC, Khachemoune A. Grover disease: Review of subtypes with a focus on management options. Int J Dermatol 2019. [Epub ahead of print]
  2. Munoz J, Guillot B, Girard C, Dereure O, Du-Thanh A. First report of ipilimumab-induced Grover disease. Br J Dermatol 2014;171:1236-7
  3. O’Gorman SM, Murphy GM. Photoaggravated disorders. Dermatol Clin 2014;32:385-98, ix
  4. Liu S, Letada PR. Successful novel treatment of recalcitrant transient acantholytic dermatosis (Grover disease) using red light 5-aminolevulinic acid photodynamic therapy. Dermatol Surg 2013;39:960-1
  5. Gantz M, Butler D, Goldberg M, Ryu J, McCalmont T, Shinkai K. Atypical features and systemic associations in extensive cases 6. Paslin D. Grover disease may result from the impairment of keratinocytic cholinergic receptors. J Am Acad Dermatol 2012;66:332-3
  6. Vangipuram R, Feldman SR. Ultraviolet phototherapy for cutaneous diseases: A concise review. Oral Dis 2016;22:253-9
  7. Paul BS, Arndt KA. Response of transient acantholytic dermatosis to photochemotherapy. Arch Dermatol 1984;120:121-2
  8. Lüftl M, Degitz K, Plewig G, Röcken M. Bath psoralen-UV-A therapy for persistent Grover disease. Arch Dermatol 1999;135:606-7
  9. Breuckmann F, Appelhans C, Altmeyer P, Kreuter A. Medium-dose ultraviolet A1 phototherapy in transient acantholytic dermatosis (Grover’s disease). J Am Acad Dermatol 2005;52:169-70.